Similar articles

• Sarcoidosis complicating treatment with adalimumab for Crohn's disease.

  McDonnell MJ, Rutherford RM, O'Regan A. McDonnell MJ, et al. J Crohns Colitis. 2014 Sep;8(9):1140-1. doi: 10.1016/j.crohns.2014.02.006. Epub 2014 Mar 13. J Crohns Colitis. 2014. PMID: 24631310 No abstract available.
• Listeria monocytogenes infection in Crohn's disease treated with adalimumab.

  Willson KJ, Jacob A, Shetti MP, Bhatia R, Yee K, Osler W. Willson KJ, et al. Med J Aust. 2012 Oct 15;197(8):466-7. doi: 10.5694/mja11.10521. Med J Aust. 2012. PMID: 23072245 No abstract available.
• Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.

  Cesarini M, Angelucci E, Foglietta T, Vernia P. Cesarini M, et al. J Crohns Colitis. 2011 Dec;5(6):619-22. doi: 10.1016/j.crohns.2011.06.010. Epub 2011 Jul 28. J Crohns Colitis. 2011. PMID: 22115384 Review.
• [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].

  Lazebnik LB, Sagynbaeva VÉ. Lazebnik LB, et al. Eksp Klin Gastroenterol. 2013;(7):18-22. Eksp Klin Gastroenterol. 2013. PMID: 24772870 Russian.
• [Efficacy and safety of Adalimumab in Crohn's disease].

  Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A. Serghini M, et al. Tunis Med. 2012 Feb;90(2):101-7. Tunis Med. 2012. PMID: 22407620 Review. French.